STERIS plc is an Ireland-incorporated, U.S.-dollar-reporting provider of infection-prevention equipment, consumables and services. Its Healthcare, Applied Sterilization Technologies and Life Sciences businesses serve hospitals, procedural facilities, medical-device manufacturers and biopharmaceutical customers.
Loading the company summary…
A snapshot of what STERIS plc owns and owes at a point in time.
Read the company’s balance sheet in the original annual reports below.
Browse original filingsSee the original statement for its reporting period, currency, and unit.
3 reports in this collection
| Report period | Filed with SEC | Form | Source |
|---|---|---|---|
| Mar 31, 20240001757898-24-000008 | May 29, 2024 | 10-K | Open 10-Ksec.gov |
| Mar 31, 20250001757898-25-000005 | May 29, 2025 | 10-K | Open 10-Ksec.gov |
| Mar 31, 20260001628280-26-039136 | May 29, 2026 | 10-K | Open 10-Ksec.gov |
Dates describe the filing metadata. Figures and reporting periods should be checked against the original statement. SEC links open in a new tab.
STERIS combines repeat-use consumables and services with equipment sales and capital-intensive sterilization infrastructure. Fiscal 2026 brought growth across all three segments, stronger cash generation and lower debt, but GAAP earnings growth also benefited materially from reduced restructuring and settlement charges. The subsequent June quarter showed continued sales and earnings growth alongside weaker working-capital cash conversion, declining AST volume and tariff-refund benefits. The largest later development is the signed, still-pending $2.1 billion Xodus acquisition, expected to be financed primarily with debt; its conditional bridge commitment is not cash or drawn borrowing. Separately, a new chemistries consolidation raises planned investment and lowers fiscal 2027 free-cash-flow guidance. These developments shift attention from historical deleveraging toward financing and execution demands, while tax disputes, sterilization regulation and constrained inputs remain material dependencies.
Sources: 10-K · 2026-03-31 · 10-Q · 2026-06-30 · EX-99.1 · 2026-08-05 · 8-K · 2026-10-11
Healthcare supplies sterile-processing and procedural equipment, consumables, repair, maintenance and outsourced reprocessing. AST provides contract sterilization and laboratory testing, while Life Sciences supports aseptic manufacturing and research. Fiscal 2026 revenue was $5,935.9 million, including $2,875.8 million of services and $1,808.4 million of consumables. STERIS calls those two categories recurring revenue, but that does not mean guaranteed subscriptions: activity depends on customer demand, and some maintenance contracts are cancellable without penalty. Equipment adds shipment timing and hospital-capital-budget exposure. The United States generated $4,333.8 million of annual revenue; Irish incorporation does not describe the main sales market.
Sources: 10-K · 2026-03-31
For the year ended March 31, 2026, reported revenue grew 8.7%; constant-currency organic growth was 7.3%. Management attributed the increase to volume and pricing, with favorable currency also contributing. Healthcare remained the largest business, but tariffs and inflation reduced its segment margin. AST and Life Sciences improved annual margins. Consolidated GAAP operating income reached $1,101.8 million, up 27.1%, versus 9.0% growth in operating income before specified adjustments. Lower restructuring charges and the absence of the prior-year Illinois EO settlement charge explain much of that difference. Continuing diluted EPS was $7.93, helped modestly by fewer diluted shares, while a higher effective tax rate offset part of operating progress.
Sources: 10-K · 2026-03-31
Fiscal 2026 operating cash flow was $1,341.4 million. Management credited higher earnings despite a smaller working-capital contribution. Company-defined non-GAAP free cash flow was $982.9 million after $369.0 million of capital purchases and including $10.5 million of asset-sale proceeds. It excludes business acquisitions and financing distributions and is not profit. At March 31, cash was $439.6 million and debt carrying value $1,931.7 million. After the annual filing, June-quarter operating cash flow fell to $367.1 million from $420.0 million despite higher earnings, principally because working capital contributed less. June 30 cash was $482.3 million and reported debt $1,893.7 million; the revolver was undrawn, not an additional cash balance.
Sources: 10-K · 2026-03-31 · 10-Q · 2026-06-30
An October 11, 2026 agreement, disclosed October 13, provides for purchasing Xodus Medical and related affiliates for $2.1 billion cash at closing, subject to adjustments, plus up to $150 million contingent on calendar 2028 performance. Closing was anticipated by December 31, subject to conditions and regulatory approvals; completion is not established. STERIS expects predominantly debt financing and obtained a conditional, reducible bridge commitment of up to $2.0 billion. Neither that commitment nor the purchase price represents cash already received or paid. Final financing costs, target earnings and quantified synergies are not supplied, so the disclosures do not establish accretion, valuation multiples or post-acquisition covenant headroom.
Sources: 8-K · 2026-10-11
The quarter ended June 30, 2026 generated $1,492.7 million revenue and $200.1 million shareholder-attributable GAAP income. Healthcare expanded its margin, but AST volume declined and both AST and Life Sciences margins narrowed. Tariff refunds benefited profit. On August 5, STERIS announced a separate North Carolina chemistries consolidation, with expected $55–70 million pretax charges and completion during fiscal 2030. Its August guidance raised fiscal 2027 capital expenditure to approximately $450 million and reduced free cash flow to approximately $800 million, while retaining revenue-growth and adjusted-EPS guidance. These forecasts predate the Xodus agreement and do not establish its financial effects.
Sources: 10-Q · 2026-06-30 · 8-K · 2026-08-05 · EX-99.1 · 2026-08-05 · 8-K · 2026-10-11
By July 31, substantially all payment obligations under the Illinois EO settlements had been satisfied and substantially all covered personal-injury claims dismissed with prejudice. That is meaningful progress, not resolution of every possible EO exposure. Regulatory restrictions, limited EO and cobalt-60 suppliers, labor costs and tariffs can still affect capacity and economics. The company also contests approximately $50 million of potential IRS tax liability, excluding interest and penalties, without a reserve. An unnamed minority investment carries conditional remaining-interest acquisition exposure. These risks coexist with reported covenant compliance and effective controls; neither disclosure establishes future financing capacity or immunity from losses.
Sources: 10-K · 2026-03-31 · 10-Q · 2026-06-30
USD 5.1387 bn
FY2024 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing
| Fiscal year | Value | YoY |
|---|---|---|
| 2024 | USD 5.1387 bn | — |
Consolidated revenue from continuing operations, retrospectively excluding Dental.
Sources: 10-K · 2026-03-31
USD 5.9359 bn
FY2026 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing
| Fiscal year | Value | YoY |
|---|---|---|
| 2026 | USD 5.9359 bn | 8.7% |
| 2025 | USD 5.4595 bn | — |
Consolidated revenue from continuing operations, excluding Dental.
Sources: 10-K · 2026-03-31
USD 785.1 m
FY2026 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing_and_discontinued
| Fiscal year | Value | YoY |
|---|---|---|
| 2026 | USD 785.1 m | 27.4% |
| 2025 | USD 616.1 m | 62.1% |
| 2024 | USD 380.1 m | — |
Net income including discontinued operations, before attribution to noncontrolling interests.
Sources: 10-K · 2026-03-31
USD 973.3 m
FY2024 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing_and_discontinued
| Fiscal year | Value | YoY |
|---|---|---|
| 2024 | USD 973.3 m | — |
Consolidated operating cash flow, including Dental discontinued operations.
Sources: 10-K · 2026-03-31
USD 1.3414 bn
FY2026 · GAAP · consolidated · Attribution: consolidated · Reported currency · operations: continuing_and_discontinued
| Fiscal year | Value | YoY |
|---|---|---|
| 2026 | USD 1.3414 bn | 16.8% |
| 2025 | USD 1.1481 bn | — |
Consolidated operating cash flow; includes Dental through its May 31, 2024 sale.
Sources: 10-K · 2026-03-31
Reading times are estimates for the English text. Financial tables and charts may take additional time.
